Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ondansetron controlled-release - RedHill Biopharma

Drug Profile

Ondansetron controlled-release - RedHill Biopharma

Alternative Names: BEKINDA; Bimodal release ondansetron; CDT-ondansetron; RHB-102

Latest Information Update: 17 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SCOLR Pharma
  • Developer RedHill Biopharma
  • Class Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Small molecules; Smoking cessation therapies
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Chemotherapy-induced nausea and vomiting; Radiotherapy-induced nausea and vomiting
  • Phase III Nausea and vomiting
  • Phase II Irritable bowel syndrome

Most Recent Events

  • 12 Sep 2018 Ondansetron controlled-release - RedHill Biopharma is available for licensing in World as of 12 Sep 2018.
  • 27 Mar 2018 Updated adverse events data from the phase III GUARD trial in Nausea and vomiting (in patients with acute gastroenteritis or gastritis) released by RedHill Biopharma
  • 26 Mar 2018 RedHill Biopharma plans one or two phase III trials of ondansetron controlled-release 12mg for Irritable bowel syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top